GI-2025-51-reg2: Clinical Trials Regulations

Pharmaceutical and biotech companies (sponsors), contract research organizations (service providers), and academic research institutions running drug clinical trials in Canada are the primary parties affected — Health Canada estimates roughly 1,311 clinical trial applications are filed annually, and about 70% use a third-party service provider. Sponsors will save an estimated $23.3 million (present value) over 10 years by no longer having to re-label already-approved drugs for trial use and by reducing adverse event record-keeping for lower-risk trials, but will face new costs of about $7.3 million (PV) for fulfilling terms and conditions, submitting additional notifications (around 1,234 more per year at roughly $523 each), and producing case/summary reports on request. Service providers — including contract research organizations — are now directly subject to regulatory obligations like good clinical practice compliance and record-keeping for the first time, which adds legal accountability but also reduces ambiguity. Only four businesses in Canada meet the definition of a small business under this framework, and their net impact is estimated to be a savings of about $167,000 each over 10 years.